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Abstract
The regulation of tumor progression towards its malignancy
needs the interplay among several cytokines, growth factors,
and enzymes, which are controlled in the tumor microenvi-
ronment. Here, we report that osteopontin, a small integrin-
binding ligand N-linked glycoprotein family of calcified
extracellular matrix–associated protein, regulates prostate
tumor growth by regulating the expression of cyclooxygenase-
2 (COX-2). We have shown that osteopontin stimulates the
activation of protein kinase C A/nuclear factor–inducing
kinase/nuclear factor-KB–dependent signaling cascades that
induces COX-2 expression, which in turn regulates the pro-
staglandin E2 production, matrix metalloproteinase-2 activa-
tion, and tumor progression and angiogenesis. We have
revealed that suppression of osteopontin-induced COX-2 ex-
pression by the nonsteroidal anti-inflammatory drug celecoxib
or blocking the EP2 receptor by its blocking antibody resulted
in significant inhibition of cell motility and tumor growth and
angiogenesis. The data also showed that osteopontin-induced
mice PC-3 xenograft exhibits higher tumor load, increased
tumor cell infiltration, nuclear polymorphism, and neovascu-
larization. Interestingly, use of celecoxib or anti-EP2 blocking
antibody drastically suppressed osteopontin-induced tumor
growth that further indicated that suppression of COX-2 or
its metabolites could significantly inhibit osteopontin-induced
tumor growth. Human clinical prostate cancer specimen
analysis also supports our in vitro and animal model studies.
Our findings suggest that blockage of osteopontin and/or
COX-2 is a promising therapeutic approach for the inhibition
of prostate tumor progression and angiogenesis. (Cancer Res
2006; 66(13): 6638-48)
Introduction
Cancer of the prostate is the most frequently diagnosed cancer
and one of the major causes of death in men especially in western
world (1). Prostate cancer progression is a series of complex events,
which require crosstalk between several oncogenic molecules, and
enable the cancer to spread and evoke angiogenesis. A high level of
constitutive cyclooxygenase-2 (COX-2) expression has been
detected in colorectal, gastric, pancreatic, head and neck, lung,
breast, and in other cancers (2). COX is an integral membrane
bifunctional enzyme, which metabolizes arachidonic acids to many
biologically active eicosanoids (3–5). There are three isoforms of
the COX enzyme (COX-1, COX-2, and COX-3). COX-1 is involved in
the production of prostaglandin (PG)–mediating cellular and
physiologic functions. The functional role of COX-3 in human
physiology and pathophysiology remains to be established (6).
COX-2 is induced in many cell types by mitogens, growth factors,
cytokines, and tumor promoters, and its increased expression is
associated with cancer progression through a PG-dependent
manner (2–5). COXs convert free arachidonic acids into PGs and
thromboxanes (3). In human prostate carcinoma, significant levels
of PGE2 has been detected, which plays an important role in cancer
progression (7). PGE2 can contribute to tumor development
through several mechanisms, including promotion of angiogenesis,
inhibition of apoptosis, increased invasiveness and motility, and
modulation of inflammation and immune responses (8–10). Recent
reports showed that COX-2 promotes tumor cell proliferation,
survival, and angiogenesis through a PGE2-mediated pathway
(10, 11).
Osteopontin, a secreted, noncollagenous, chemokine-like small
integrin-binding ligand N-linked glycoprotein family of protein
plays significant role in determining the oncogenic potential of
various cancers and recognized as a key marker in the processes of
tumorigenicity and metastasis (12). Osteopontin is an acidic
glycoprotein with a molecular mass varying from 44 to 75 kDa,
depending on the degree of posttranslational modification (13). It
has an NH2-terminal signal sequence, a sialic acid region consisting
of nine consecutive aspartic acid residues, a GRGDS cell adhesion
sequence that is predicted to be flanked by h-sheet structure (14).
Osteopontin interacts with several integrins and CD44 variants in
an RGD sequence–dependent and RGD sequence–independent
manner (15, 16). Osteopontin is involved in normal tissue
remodeling processes, such as bone resorption, wound healing,
and tissue injuries as well as restenosis, atherosclerosis, tumor-
igenesis, and autoimmune diseases (17, 18). Previous studies
indicated that osteopontin plays crucial role in chemotaxis and
chemoinvasion of PC-3 cells (19). Recent data also showed that
osteopontin induces pro-matrix metalloproteinase-2 (pro-MMP-2)
and pro-MMP-9 activation, urokinase plasminogen activator (uPA)
secretion, cell motility, extracellular matrix invasion, and tumor
growth (20, 21).
Cell motility, a major step in cancer metastasis, is often
associated with the activation of protein tyrosine or serine kinases,
like c-Src and protein kinase C a (PKCa), respectively. Previous
studies have indicated that c-Src and PKCa play crucial roles
in COX-2 expression and COX-2-dependent tumor progression
(22–24). The transcription factor nuclear factor-nB (NF-nB) act as a
key molecule in regulating wide range of physiologic and
pathologic processes (25). Nuclear factor inducing kinase (NIK), a
member of mitogen-activated protein kinase kinase kinase
(MAPKKK) family has been reported to activate NF-nB through
phosphorylation and degradation of InBa (26). We have recently
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reported that osteopontin induces uPA secretion and MMP-2/
MMP-9 activation through c-Src/phosphatidylinositol 3-kinase/
MAPK signaling pathways (20, 21, 27). However, the molecular
mechanism by which osteopontin regulates PKCa/c-Src–depen-
dent InB kinase (IKK)–mediated NF-nB activation, which ulti-
mately regulates tumor progression and angiogenesis through
induction of COX-2 expression in prostate cancer and signaling
cascades, underlying these processes are not well defined.
In this study, we provide both in vitro and in vivo experimental
evidences, at least in part, the molecular mechanism by which
osteopontin regulates PKCa/c-Src/IKK/NF-nB signaling cascades
leading to COX-2-mediated PGE2 production and MMP-2 activa-
tion in prostate cancer. Furthermore, we have shown that
osteopontin-induced COX-2 regulates cell motility, angiogenesis,
and tumorigenesis of prostate cancer through both autocrine and
paracrine pathways. However, suppression of COX-2 activity by
nonsteroidal anti-inflammatory drug (NSAID) celecoxib or blocking
the interaction between PGE2 and its receptor EP2 by using specific
anti-EP2 blocking antibody significantly suppressed osteopontin-
induced in vitro cell motility, invasiveness, and in vivo tumor
growth. Moreover, the clinical data indicated that the increased
expressions of osteopontin and COX-2 correlate with enhanced
MMP-2 expression and angiogenesis in prostate cancer specimens
of higher grades. Consequently, osteopontin plays important and
essential role in two key aspects of tumor progression: COX-2-
mediated PGE2 production and MMP-2 activation by tumor cells
leading to tumor progression and COX-2/PGE2–stimulated angio-
genesis. Our findings suggest that blockade of osteopontin and
COX-2 is a promising therapeutic approach for the inhibition of
tumor progression by suppressing tumor growth and angiogenesis.
Materials and Methods
Antibodies and reagents. Rabbit polyclonal anti-COX-2, anti-PKCa,
anti-NIK, anti-p-NIK(Thr559), anti-IKKa/h, anti-NF-nB, p65, anti-MMP-2,
anti-c-Src, anti-EP2, and anti-actin, mouse monoclonal anti-phosphotyr-
osine, goat polyclonal anti-phospho-PKCa (Ser657) antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit
polyclonal anti-p-IKKa/h (Ser180/Ser181) antibody was from Cell Signaling
Technology (Beverly, MA); goat polyclonal anti-osteopontin antibody was
from R&D Systems (Minneapolis, MN); and rabbit polyclonal anti-human
vWF antibody was purchased from Sigma (St. Louis, MO). The [g-32P]ATP
was purchased from Board of Radiation and Isotope Technology
(Hyderabad, India). All other chemicals were of analytic grade. The human
osteopontin was purified from milk as described previously (20), with a
minor modification, and used throughout this study.
Cell culture. The human prostate cancer (PC-3) cells were obtained
from the American Type Culture Collection (Manassas, VA). Human
umbilical vein endothelial cell line EA.hy-926 was a generous gift from Dr.
Christopher Newton (University of Hull, United Kingdom). PC-3 cells were
cultured in F-12 HAM Nutrient Mixture (Sigma), and EA.hy-926 cells were
cultured in DMEM (Sigma) supplemented with 10% FCS, 100 units/mL
penicillin, 100 Ag/mL streptomycin, and 2 mmol/L glutamine in a
humidified atmosphere of 5% CO2 and 95% air at 37jC.
Plasmids and DNA transfection. The full-length osteopontin cDNA was
a generous gift from Dr. Ann Chambers (University of Western Ontario,
London, Ontario, Canada). The dominant-negative c-Src (pcSrcY527F/S12A)
and COX-2-Luc (1432/+59) constructs were generous gifts from Dr. David
Shalloway (Cornell University, NY) and Dr. Hiroyashu Inoue (Osaka, Japan;
ref. 28), respectively. The wild-type NIK (wt pcDNA NIK) and kinase-
negative NIK (mut pc DNA NIK and NIK-K429A/K430A) in pcDNA3 were
obtained from Prof. David Wallach (Weizmann Institute of Science,
Rehovot, Israel). The wild-type and dominant-negative constructs of IKKa
(wt IKKa and dn IKKa) and IKKh (wt IKKh and dn IKKh) in
PKC-related kinase were kind gifts from Prof. D.V. Goeddel (Tularik, Inc.,
San Francisco, CA). The super-repressor form of InBa cDNA fused
downstream to a FLAG epitope in an expression vector (pCMV4) was a
gift from Dr. Dean Ballard (Vanderbilt University School of Medicine,
Nashville, TN). PC-3 cells were split 16 hours before transfection and
transiently transfected with cDNA using LipofectAMINE 2000 reagent
according to manufacturer’s instructions (Invitrogen, San Diego, CA). The
cell viability was detected by trypan blue dye exclusion test. Transfected
cells were used for COX-2 expression, COX-2 promoter analysis studies, IKK
and p65 phosphorylation, and PKCa kinase assay and migration and
invasion assays.
Small interfering RNA. PC-3 cells were transfected with small
interfering RNA (siRNA) that specifically targets the osteopontin gene or
nonsilencing control using LipofectAMINE-2000 according to manufac-
turer’s instructions. siRNA duplexes were synthesized by Dharmacon, Inc.
(Lafayette, CO). The sequence targeted for osteopontin is 5¶-GUUUCA-
CAGCCACAAGGACdTdT/dTdTCAAAGUGUCGGUGUUCCUG-5¶, and the
nonsilencing control is 5¶-CAGUACAACGCAUCUGGCAdTdT/dTdTGUCAU-
GUUGCGUAGACCGU-5¶.
Western blot and immunoprecipitation. The level of COX-2, PKCa
c-Src, osteopontin, IKKa/h, actin expressions and phosphorylations of
IKKa/h and NF-nB, p65 in transfected or treated PC-3 cells were analyzed
by Western blot using its specific antibody (20). The tyrosine phosphory-
lation of IKKa/h and the interaction between PKCa and c-Src were done by
immunoprecipitation followed by Western blot.
RNA extraction and reverse transcription-PCR. Total RNA was
isolated from osteopontin-treated PC-3 cells and analyzed by reverse
transcription-PCR (RT-PCR). The reverse transcription and PCR amplifica-
tion used 10 Ag of total RNA, with Moloney murine leukemia virus reverse
transcriptase (Invitrogen) and primers COX-2 forward (5¶-TTCAAATGA-
GATTGTGGGAAAATTGCT-3¶) and COX-2 reverse (5¶-AGATCATCT-
CTGCCTGAGTATCTT-3¶) to reverse transcribe sense and antisense RNAs,
respectively (29). The amplified cDNA fragments were resolved by 2%
agarose gel electrophoresis.
COX-2 luciferase assay. The semiconfluent PC-3 cells were grown in 24-
well plates and transiently transfected with COX-2 luciferase reporter
construct using LipofectAMINE 2000. In separate experiments, cells were
individually transfected with wt and mut NIK and wt and dn IKKh along
with COX 2 luciferase construct. The transfection efficiency was normalized
by cotransfecting the cells with pRL vector (Promega, Madison, WI)
containing a full-length Renilla luciferase gene under the control of a
constitutive promoter. After 24 hours of transfection, the cells were treated
with 0.5 Amol/L osteopontin, and the luciferase activities were measured by
luminometer (Thermo Electron) using the dual luciferase assay system
according to the manufacturer’s instructions (Promega). Changes in the
luciferase activity with respect to control were calculated.
Estimation of PGE2. The levels of PGE2 from the conditioned media of
osteopontin-treated PC-3 cells and mice plasma were detected by using the
Biotrack PGE2 competitive enzyme immunoassay kit (Amersham Bioscien-
ces, Piscataway, NJ) according to the manufacturer’s instructions.
In vitro kinase assay by autophosphorylation study. In vitro kinase
assay was done as described earlier (30). Briefly, PC-3 cells were either
treated with osteopontin (0.5 Amol/L) for 5 minutes or pretreated with 100
nmol/L staurosporine (Calbiochem, La Jolla, CA) for 3 hours or transfected
with dn c-Src and then treated with osteopontin. Cell lysates were
immunoprecipitated with anti-PKCa and anti-c-Src antibodies. Autophos-
phorylation of PKCa and c-Src were measured by incubating the
immunoprecipitated samples with 40 ACi of [g32P]ATP in 40 AL kinase
assay buffer [20 mmol/L HEPES (pH 7.7), 2 mmol/L MgCl2, 10 mmol/L
h-glycerophosphate, 10 mmol/L NaF, 10 mmol/L pNPP, 300 Amol/L Na3VO4,
1 mmol/L benzamidine, 2 Amol/L phenylmethylsulfonyl fluoride, 10 Ag/mL
aprotinin, 1 Ag/mL leupeptin, 1 Ag/mL pepstatin, and 1 mmol/L DTT] for
30 minutes at 30jC. Reactions were terminated by the addition of sample
buffer and analyzed by SDS-PAGE followed by autoradiography.
Zymography. The gelatinolytic activity was measured as described
previously (20). Briefly, PC-3 cells were either treated with osteopontin
or pretreated with staurosporine and COX-2 inhibitor (Celecoxib) or
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transfected with dn c-Src and then treated with osteopontin. Conditioned
medium was collected, and gelatinolytic activity of MMP-2 was detected by
zymography.
Cell migration and invasion assay. The migration and invasion assays
were done using Transwell cell culture chamber (Corning, Corning, NY) and
Matrigel coated invasion chambers (Collaborative Biomedical, Bedford,
MA), respectively, according to the standard procedure as described
previously (27). Briefly, the confluent monolayers of PC-3 (treated or
transfected) cells were harvested with trypsin-EDTA and centrifuged at 800
 g for 10 minutes. The cell suspension (2  105 per well) was added to the
upper chamber. The lower chamber was filled with fibroblast-conditioned
medium, which acted as a chemoattractant. In separate experiments,
osteopontin-treated conditioned medium of PC-3 cells was incubated with
EA.hy-926 cells alone or along with anti-EP-2 blocking antibody and
subjected to migration and invasion assays. After 12 hours, cells in the lower
chamber were fixed and stained with Giemsa stain and counted in three
high-power fields (C/HPF) under an inverted microscope (Olympus). Data
are presented as the average of three counts FSE.
Wound assay. The wound assay was done as described (31). Briefly, the
post-confluent PC-3 cells with typical cobblestone morphology were used in
this experiment. Wounds with a constant diameter were made. Cells were
treated with osteopontin alone or along with EP2 blocking antibody or
celecoxib (COX-2 inhibitor). In other experiments, EA.hy-926 cells were
incubated with conditioned media obtained from osteopontin-treated PC-3
cells either alone or along with EP2 blocking antibody, and wound assay was
conducted. The wound photographs were taken under phase-contrast
microscope (Olympus).
PC-3 xenograft tumor model. The tumorigenicity experiments were
done as described previously (27). Briefly, PC-3 cells (5  105) were mixed
with an equal volume of cold Matrigel and then injected s.c. into the dorsal
side of the athymic nude mice (NMRI, nu/nu ; NIV, Pune, India). Osteopontin
alone or along with anti-EP-2 blocking antibody (20 Ag) was injected into
tumor sites twice a week for up to 4 weeks. In other experiments, celecoxib
(1,500 ppm) was given along with diet of the osteopontin-injected animals
as described earlier (32). Three mice were used in each set of experiments.
The mice were kept under pathogen-free conditions. Growths of s.c. tumors
were monitored weekly by measuring the tumors with calipers. At the
termination of the experiment, blood was collected from the retro-orbital
plexus under anesthesia from both experimental and control groups.
Animals were sacrificed by cervical dislocation, and tumors were excised
and weighed. The tumor samples were used for histopathologic and
immunohistochemical studies using standard procedure (33). The expres-
sions of COX-2, MMP-2, and vWF (endothelial cell–specific marker) were
determined by immunofluorescence using their specific antibodies. The
slides were analyzed under confocal microscopy (Zeiss, Jena, Germany).
Human prostate clinical sample analysis. Human prostate tumor
specimens of different Gleason grades and normal prostate tissues were
collected from a local hospital with informed consent. The COX-2,
osteopontin, MMP-2, and vWF expressions were detected by immunoflu-
orescence using specific antibodies. Five samples of each group [normal,
low grade (prostatic intraepithelial neoplasia or PIN), and malignant] were
analyzed. Normal prostate tissues were used as control.
Statistical analysis. The data reported in cell migration, wound healing,
and invasion are expressed as mean FSE. Statistical differences were
determined by two-way ANOVA and Student’s t test. P < 0.05 was considered
significant. All these bands were analyzed densitometrically (Kodak Digital
Science, Rochester, NY), and the fold changes were calculated.
Results
Osteopontin augments COX-2 protein and mRNA expres-
sion. To determine whether osteopontin augments COX-2
expression, PC-3 cells were treated with 0.5 Amol/L osteopontin
for 0 to 24 hours. Expression of COX-2 in cell lysates was
detected by Western blot, and the data indicated that osteopontin
Figure 1. Osteopontin (OPN ) induces COX-2 promoter activity and expression in PC-3 cells. A, serum-starved PC-3 cells were treated with 0.5 Amol/L osteopontin for
0 to 24 hours. The level of COX-2 from whole-cell lysates was analyzed by Western blot. Actin was used as loading control. B, cells were treated with osteopontin
(0-0.5 Amol/L) for 6 hours; total RNA was isolated; and RT-PCR analysis was done using COX-2-specific primers. Changes in mRNA levels were determined as
fold of induction. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control. C, PC-3 cells were transfected with osteopontin cDNA,
osteopontin-specific siRNA, or nonsilencing scrambled siRNA. In separate experiments, osteopontin siRNA–transfected cells were either cotransfected with osteopontin
cDNA or treated with 0.5 Amol/L osteopontin. COX-2 was analyzed by Western blot. The level of osteopontin is also detected by Western blot. Actin was used as loading
control. D, osteopontin enhances NIK/IKK–mediated COX-2 promoter activity. Cells were transfected with luciferase reporter construct (COX-2-Luc) and then
treated with 0 to 0.5 Amol/L osteopontin or cotransfected with wt and mut NIK or wt and dn IKKh and then treated with 0.5 Amol/L osteopontin. Cell lysates were used to
measure the luciferase activity. The values were normalized to Renilla luciferase activity. The fold changes were calculated. Columns, mean of triplicate determinations;
bars, SE.
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induced maximum COX-2 expression at 24 hours (Fig. 1A). The
dose-dependent effect of osteopontin (0-1 Amol/L) on COX-2
expression was also detected, and the results indicated that
osteopontin at 0.5 Amol/L exhibits maximum level of COX-2
expression in PC-3 cells (data not shown). The COX-2 mRNA level
was also determined by RT-PCR, and the data indicated that
osteopontin at 0.5 Amol/L enhanced maximum COX-2 expression
at transcriptional level (Fig. 1B). Interestingly, our results also
showed that osteopontin induced COX-2 expression in other
prostate cancer cell lines like DU-145 and LNCaP (data not shown).
To examine the specificity of osteopontin on COX-2 expression,
cells were transfected with wt osteopontin cDNA alone or
cotransfected with osteopontin siRNA duplex and control RNA
duplex. The data showed that cells transfected with osteopontin
cDNA enhanced the COX-2 expression. Cells transfected with
osteopontin cDNA followed by siRNA duplex suppressed the
osteopontin-induced COX-2 expression (Fig. 1C). Our results
indicated that osteopontin enhanced COX-2 expression both at
transcriptional and translational levels.
Osteopontin enhances NIK/IKK/NF-KB–dependent COX-2
promoter activity. The effect of osteopontin on COX-2 promoter
activity was determined by transfecting PC-3 cells with COX-2
luciferase construct followed by treatment with osteopontin in a
dose-dependent manner. In separate experiments, cells were
cotransfected with wt NIK or IKKh or kinase-negative (mut) NIK
or dn IKKh along with COX-2 luciferase construct and then treated
with osteopontin. Further transfecting the cells with pRL construct
normalized the transfection efficiency, and COX-2 luciferase
activities were measured according to standard procedure. The
results showed that cells transfected with wt NIK or IKKh
enhanced the COX-2 promoter activity, whereas mut NIK or dn
IKKh significantly suppressed osteopontin-induced COX-2 pro-
moter activity (Fig. 1D). Cells transfected with wt IKKa enhanced
osteopontin-induced COX-2 promoter activity, whereas dn IKKa or
the super-repressor form of InBa suppressed osteopontin-induced
COX-2 promoter activity (data not shown). These results indicated
that osteopontin enhanced COX-2 promoter activity through a
NIK/IKK–dependent NF-nB-mediated pathway.
Osteopontin regulates PKCA/c-Src–dependent IKK/NF-KB–
mediated COX-2 expression. Recent reports revealed that PKCa
plays important role in the survival and growth of androgen-
independent human prostate cancer (PC-3) cells (34). It is well
established that PKCa plays crucial role in COX-2 expression (23).
Therefore, to delineate the effect of osteopontin on PKCa
phosphorylation and its interaction with c-Src, cells were treated
with osteopontin for 0 to 7 minutes, and one part of the cell lysates
was analyzed by Western blot using anti-phospho-PKCa antibody
(Fig. 2A, a, top). The remaining part of lysates was immunopre-
cipitated with anti-c-Src antibody, and the interaction between
phosphorylated PKCa and c-Src was determined by Western blot
using anti-phospho-PKCa antibody (Fig. 2A, b, top). The same blots
were reprobed with anti-PKCa and c-Src antibody, respectively, as
Figure 2. Osteopontin (OPN ) induces PKCa activation, PKCa-mediated c-Src and IKK phosphorylation, and COX-2 expression. A, PC-3 cells were treated with
osteopontin for 0 to 7 minutes, and the phosphorylation of PKCa was detected by Western blot using anti-phospho-PKCa antibody (p-PKCa ; a, top ). The cells
were treated with osteopontin for 0 and 5 minutes, and cell lysates were immunoprecipitated with anti-c-Src antibody and analyzed by Western blot using
anti-phospho-PKCa antibody (b, top ). Levels of PKCa and c-Src were detected by reprobing the same blots with their specific antibodies (a and b, bottom ). B, cells
were either transfected with dn c-Src or pretreated with staurosporine (Stau , a PKC inhibitor, 100 nmol/L) and then treated with osteopontin for 5 minutes. Cell
lyates were immunoprecipitated with anti-PKCa or anti-c-Src antibody, and the kinase activity of PKCa (a) and c-Src (b ) was determined by autophosphorylation
experiment and visualized by autoradiography. C, cells were individually transfected with dn c-Src, wt and mut NIK, or pretreated with staurosporine and then treated
with osteopontin. Half of the cell lysates were analyzed by Western blot using anti-phospho-Ser-IKKa/h (Ser180/Ser181) antibody (top), and the remaining part of cell
lysates was immunoprecipitated with IKKa/h antibody and detected by Western blot using anti-phosphotyrosine antibody (middle ). The level of IKKa/h was also
detected by Western blot (bottom ). D, cells were pretreated with staurosporine or individually transfected with dn c-Src, InBa super-repressor (sup. rep. ), wt and dn
IKKa or IKKh, and wt or mut NIK and then treated with osteopontin. COX-2 expression was detected by Western blot. Actin was used as loading control. Represents
three experiments exhibiting similar results. Fold changes were calculated.
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loading controls (Fig. 2A, a and b, bottom). The results indicated
that osteopontin enhanced PKCa phosphorylation and its interac-
tion with c-Src. To determine the role of avh3 integrin on
osteopontin-induced PKCa phosphorylation, cells were pretreated
with anti-human avh3 integrin blocking antibody, RGD, or RGE
(GpenGRGDSPCA and GRGESP, respectively) peptides and then
treated with osteopontin, and the level of PKCa phosphorylation was
detected by immunoblotting. The results indicated that anti-avh3
integrin blocking antibody and GpenGRGDSPCA but not GRGESP
suppressed the osteopontin-induced PKCa phosphorylation (data
not shown). The data suggested that avh3 integrin plays an
important role in osteopontin-induced PKCa phosphorylation. To
delineate whether PKCa is upstream of c-Src or vice versa, cells were
pretreated with PKCa inhibitor (staurosporine) and treated with
osteopontin, and cell lysates were immunoprecipitated with anti-
c-Src antibody. The immunoprecipitated samples were analyzed for
c-Src autophosphorylation by in vitro kinase assay. Similarly, in other
experiments, cells were transfected with dn c-Src and treated with
osteopontin, and cell lysates were immunoprecipitated with anti-
PKCa. The immunoprecipitated samples were used for in vitro PKCa
kinase assay. The data showed that dn c-Src has no effect on PKCa
autophosphorylation, whereas PKCa inhibitor suppressed c-Src
phosphorylation, suggesting that osteopontin regulates PKCa-
dependent c-Src activation (Fig. 2B, a and b, top). The levels of
PKCa and c-Src in the same lysates were detected by Western blot
using their specific antibodies as controls (Fig. 2B, a and b, bottom).
Furthermore, suppression of PKCa and c-Src resulted in inhibition of
osteopontin-induced NIK phosphorylation (data not shown). To
determine whether these upstream kinases (PKC, c-Src, and NIK)
play any role in osteopontin-induced IKKa/h phosphorylation, cells
were individually transfected with dn c-Src or wt and mut NIK or
pretreated with PKCa inhibitor (staurosporine) and then treated
with osteopontin. Cell lysates were analyzed either by Western blot
using anti-phosphoserine IKKa/h antibody or immunoprecipitated
with anti-IKKa/h antibody followed by immunoblotting with
anti-phosphotyrosine antibody (Fig. 2C, top and middle). These
data showed that both PKC inhibitor and dn c-Src suppressed
osteopontin-induced serine and tyrosine phosphorylations of IKKa/
h, whereas mut NIK inhibits only the serine but not tyrosine
phosprylation of IKKa/h, suggesting that NIK plays differential role
in osteopontin-induced PKCa/c-Src–mediated IKKa/h activation
(Fig. 2C, top and middle). The level of IKK a/h was also detected by
Western blot as control (Fig. 2C, bottom).
To further investigate whether PKCa, c-Src, NIK, IKK, and NF-nB
play any role in osteopontin-induced COX-2 expression, cells were
pretreated with PKC inhibitor (staurosporine) or individually
transfected with dn c-Src, wt and mut NIK, and InBa super-
repressor, wt and dn IKKa or IKKh followed by treatment with
osteopontin. The COX-2 expression was detected by Western blot
(Fig. 2D). These results suggested that PKCa and c-Src play an
important role in regulating osteopontin-induced COX-2 expres-
sion through a NIK/IKK/NF-nB–mediated pathway.
Osteopontin induces PKCA/c-Src–mediated p65 phosphor-
ylation. Recent findings suggested that phosphorylation of p65
subunit of NF-nB leads to nuclear translocation and activation of
NF-nB (35), and that the promoter region of COX-2 contains the
NF-nB response element (36). In Fig. 2D , we showed that
suppression of NF-nB by overexpression of InBa super-repressor
significantly inhibits osteopontin-induced COX-2 expression.
Therefore, we sought to determine whether osteopontin regulates
NF-nB, p65 phosphorylation that ultimately regulates COX-2
expression, and whether PKCa and c-Src are involved in this
process. Accordingly, cells were treated with osteopontin from 0 to
180 minutes or pretreated with PKC inhibitor (staurosporine) or
transfected with dn c-Src and then treated with osteopontin. The
level of p65 phosphorylation in the cell lysates was detected by
Figure 3. Osteopontin (OPN ) induces
PKCa/c-Src–dependent NF-nB, p65
phosphorylation, MMP-2 activation, and
PGE2 production. A, PC-3 cells were
treated with osteopontin for the indicated
time, and the level of phospho-p65 (p-p65 ;
Ser536) from cell lysates were detected by
Western blot (top ). B, cells were
transfected with dn c-Src or pretreated with
staurosporine (Stau ) and then treated
with osteopontin. The level of phospho-p65
was analyzed by Western blot. The level of
non-phospho-p65 was also detected by
Western blot (A and B, bottom ). C, cells
were transfected with dn c-Src or
pretreated with staurosporine or celecoxib
(COX-2 inhibitor, 50 Amol/L) and then
treated with osteopontin for 24 hours.
Conditioned media were collected, and the
level of MMP-2 activation was detected by
zymography. Recombinant MMP-2
(r MMP-2) was used as positive control.
D and E, cells were treated with 0.5 Amol/L
osteopontin for 0 to 24 hours. In separate
experiments, cells were transfected with
dn c-Src or pretreated with staurosporine
and celecoxib and then treated with
osteopontin for 24 hours. Conditioned
media were collected, and the level of
PGE2 was estimated by enzyme
immunoassay. Represents three
experiments exhibiting similar results.
Cancer Research
Cancer Res 2006; 66: (13). July 1, 2006 6642 www.aacrjournals.org
Western blot using anti-phospho-p65 antibody (Fig. 3A and B). The
results showed that inhibition of PKCa and c-Src significantly
suppressed osteopontin-induced NF-nB, p65 phosphorylation
(Fig. 3B). These results clearly suggested that osteopontin induces
p65 phosphorylation through a PKCa/c-Src–dependent pathway,
which leads to NF-nB activation that ultimately regulates COX-2
expression.
Osteopontin augments COX-2-mediated PGE2 production
and MMP-2 activation. Earlier reports revealed that overexpres-
sion of COX-2 leads to up-regulation of arachidonic acid
metabolism, which in turn results in enhancement of PGE2
production and tumor progression (2, 37–39). Accordingly, to
determine whether osteopontin can induce COX-2-mediated PGE2
production, cells were treated with osteopontin for 0 to 24 hours,
and the PGE2 level in the conditioned media was measured by
using PGE2 enzyme immunoassay kit. To examine whether PKC,
c-Src, and COX-2 are involved in osteopontin-induced PGE2
production, cells were pretreated with PKC inhibitor (staurospor-
ine) or COX-2 inhibitor (celecoxib) or transfected with dn c-Src and
then treated with osteopontin. The results indicated that inhibitors
of PKC and COX-2 and dn c-Src drastically suppressed the
osteopontin-induced PGE2 production (Fig. 3D and E). To delineate
the role of PKCa, c-Src, and COX-2 in osteopontin-induced MMP-2
activation, cells were treated or transfected as described earlier,
and the level of active MMP-2 in the conditioned medium was
determined by zymography (Fig. 3C). These results showed that
COX-2 plays a crucial role in osteopontin-induced PKC/c-Src–
mediated PGE2 production and MMP-2 activation in prostate
cancer cells.
COX-2 and PGE2 play an important role in osteopontin-
induced PC-3 cell migration and invasion. Previous data
suggested that COX-2 and its metabolite PGE2 act as crucial
molecules in regulating tumor cell motility, invasiveness, and
tumor metastasis (2). Therefore, to examine the role of COX-2 and
PGE2 in osteopontin-mediated PC-3 cell migration, the wound
assay was done. Cells were either pretreated with PKC inhibitor
(staurosporine), celecoxib, or anti-EP2 antibody or transfected with
dn c-Src. Wounds with a constant diameter were made, and cells
were treated with osteopontin. The wound photographs were taken
under phase-contrast microscope (Fig. 4A). These data showed
that inhibition of COX-2 or its upstream kinases (PKCa and c-Src)
resulted in significant suppression of osteopontin-induced PC-3
cell motility towards the wound and further indicated that COX-2
act as a key molecule in osteopontin-induced tumor cell migration.
Interestingly, blocking the interaction between PGE2 and its
receptor EP2 by using specific anti-EP2 blocking antibody also
suppressed osteopontin-induced tumor cell motility, indicating
that osteopontin regulates wound migration via COX-2-dependent
PGE2 production through interaction with its receptor EP2 in an
autocrine fashion. The wound migration data were further
confirmed by modified Boyden chamber migration and extracel-
lular matrix invasion assays. The results indicated that the cell
migration due to over expression of wt NIK, IKKa, or IKKh in
response to osteopontin was suppressed by the celecoxib,
suggesting the potential role of COX-2 in osteopontin-induced
NIK/IKK–dependent tumor cell migration and invasion (Fig. 4B
and C). To examine the specificity of COX-2 in osteopontin-induced
cell migration, NS398 (NSAID), a COX-2 inhibitor, was used, and the
data showed that NS398 is also suppressed osteopontin-induced
cell migration and invasion. PGE2 was used as a positive control.
Taken together, these data indicated the potential and crucial role
of COX-2 and PGE2 in osteopontin-induced tumor cell motility and
invasiveness.
Osteopontin-induced tumor cell–derived PGE2 enhanced
endothelial cell motility and invasiveness through paracrine
mechanism. Earlier data indicated that tumor-derived PGE2
Figure 4. Inhibition of the PKC, c-Src, and
COX-2 or blocking of EP2 receptor
suppressed osteopontin (OPN )–induced
PC-3 cell motility and invasiveness.
A, cells were transfected with dn c-Src,
or pretreated with staurosporine (Stau ),
celecoxib, or anti-EP2 blocking antibody
(4 Ag) then treated with osteopontin for
12 hours. Wound assays were done as
described earlier. Wound photographs
were taken at initial time (0 hour) and the
termination of the experiments (12 hours).
The experiments were repeated in
triplicate. B, cells were individually
transfected with wt NIK and IKKa and IKKh
and treated with celecoxib. In separate
experiments, cells were transfected with
dn c-Src or treated with staurosporine,
celecoxib, NS398, and EP2 blocking
antibody and used for migration assay.
Osteopontin was used in the upper
chamber. PGE2 was used as positive
control. After 12 hours, migrated cells were
counted from the lower chamber and
represented graphically. C, experiments
paralleling those of (B) but measuring
invasion rather than migration. Columns,
means of three determinations; bars, SE.
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interacts with the endothelial cell surface receptor and induced
endothelial cell motility and invasiveness that leads to tumor
angiogenesis (38). It is reported that EP2 act as one of the main
PGE2 receptor in endothelial cells (39). To determine whether
osteopontin-induced PC-3 cell–derived PGE2 enhances endothelial
cell migration and invasion through EP2-mediated paracrine
manner, endothelial cells were used on the upper side of modified
Boyden or Matrigel-coated invasion chamber. The conditioned
media collected from osteopontin-treated PC-3 cells were used as
chemoattractrant (Fig. 5A and B). In separate experiments,
endothelial cells were pretreated with anti-EP2 blocking antibody
and used for migration and invasion assays. Our data showed that
conditioned media of osteopontin-treated PC-3 cells significantly
enhanced endothelial cell migration and invasion, whereas block-
ing the EP2 receptor in these cells with its antibody significantly
suppressed the endothelial cell migration and invasion (Fig. 5A and
B). The enhanced migration of endothelial cells was further
confirmed by wound assay under the same experimental condition
(Fig. 5C). Our results indicated that osteopontin-induced tumor
cell–derived PGE2 enhanced migration and invasion of endothelial
cells through an EP2-mediated paracrine mechanism.
Development of PC-3 xenograft model to study the role of
COX-2 in osteopontin-induced tumor progression. Our in vitro
results prompted us to study the role of COX-2 and PGE2 in
osteopontin-induced mice xenograft tumor progression. Accord-
ingly, PC-3 cells (5  105) were mixed with Matrigel and then
injected s.c. into the dorsal flanks of the male athymic nude mice.
In other experiments, cells were treated with osteopontin alone or
along with anti-EP2 blocking antibody and then injected into the
nude mice. The osteopontin alone or mixture of osteopontin and
anti-EP2 antibody was also injected to the tumor sites twice a week
for up to 4 weeks. In another experiments, celecoxib (1,500 ppm)
was supplemented to the normal diet of the osteopontin-injected
animals. All the mice were kept under pathogen-free conditions.
Figure 6A (a-d) showed typical photographs of tumors grown in
nude mice. Blood was collected; mice were sacrificed by cervical
dislocation; and tumors were excised, weighed, and measured
(Table 1). Tumor samples were used for histopathologic and
immunohistochemical studies according to standard procedure.
The histopathologic analysis by H&E staining is summarized in
Table 2, and these data clearly indicated that osteopontin-induced
tumorigenicity in nude mice was suppressed significantly by anti-
EP2 blocking antibody or by supplementation of celecoxib in mice
diet (Table 2; Fig. 6A, e-h). Moreover, the immunohistochemical
studies showed that the enhanced expressions of COX-2 and MMP-
2 were detected in mice treated with osteopontin (Fig. 6A, i-p). The
expression of vWF (an endothelial cell–specific marker) was also
detected (Fig. 6A, q-t). The plasma PGE2 level was also higher in
osteopontin injected mice (Fig. 6B). Taken together, our in vivo
xenograft study showed that osteopontin induces prostate tumor
growth and angiogenesis in nude mice that is correlated with
up-regulation of COX-2 expression, MMP-2 activation, and PGE2
secretion. Inhibition of COX-2 or blocking of EP2 receptor signi-
ficantly suppressed osteopontin-induced angiogenesis and tumor
progression in nude mice and further showed that COX-2
plays an important role in osteopontin-induced prostate cancer
progression.
Expressions of osteopontin, COX-2, MMP-2, and NF-KB, p65
localization, and their correlation with human prostate
cancer progression and angiogenesis in different pathologic
grades. To correlate the in vitro data and in vivo mouse model
results with human clinical specimens, human prostate cancer
tissues were collected from a local hospital with informed consent.
The tumor samples were stained with H&E, and the grades of these
samples were determined by Gleason grading system with the help
of expert histoplathologist (Fig. 7A, a-c). Expression of osteopontin,
COX-2, MMP-2, and vWF and cellular localization of p65
were analyzed by immunohistochemistry using their specific
Figure 5. Osteopontin (OPN ) stimulates
EP2-mediated endothelial cell migration,
invasion, and wound healing via paracrine
mechanism. A, human endothelial
(EA.hy-926) cells were added in the upper
chamber. The conditioned medium (CM)
collected from PC-3 cells treated with
osteopontin was used as chemoattractant
in the lower chamber. In separate
experiments, EA.hy-926 cells were treated
with anti-EP2 blocking antibody and used
for migration assay. After 12 hours,
migrated cells were counted as described
earlier. B and C, experiments paralleling
those of (A ) but measuring invasion
and wound healing rather than migration.
Columns, means of three determinations;
bars, SE.
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antibodies (Fig. 7A, d-r). These results indicated the higher levels of
osteopontin and COX-2 in malignant tumors than normal and PIN,
and that further correlated with the enhanced MMP-2 expression
and neovascularization (vWF expression). Moreover, there was
significant nuclear translocation of p65 in the malignant tumors.
All these data correlate with our in vitro and mice xenograft
studies.
Discussion
The interaction between osteopontin and prostate cancer cells
are likely to be the key determinants in regulating tumor
progression and metastatic phenotype of human prostate carcino-
ma and further indicates that osteopontin may be an important
mediator of prostate cancer progression (40). Recent strategies in
therapeutics of prostate cancers with inhibitors that target COX-2
(41) and its enhanced expression in prostate carcinoma suggest
that understanding the molecular mechanism underlying enhanced
COX-2 expression may help in developing the novel therapeutic
approach in prostate cancer treatment. The experimental work
presented in the study showed for the first time the molecular
mechanism that underlies osteopontin-induced COX-2 expression
and its potential role in regulating in vitro cell motility and
invasion of prostate cancer, which ultimately modulates in vivo
tumor growth and angiogenesis. Silencing of osteopontin in pros-
tate cancer cells results drastic reduction, whereas overexpression
of osteopontin significantly increased COX-2 level, suggesting the
specificity of osteopontin on COX-2 expression. Moreover, we find
that COX-2 plays an important role in osteopontin-induced PGE2
production and MMP-2 activation that ultimately regulates tumor
progression.
Figure 6. COX-2 and PGE2 play crucial roles in osteopontin (OPN )–induced tumorigenesis and angiogenesis in nude mice. A, photographs of athymic mice showing
4-week-old xenograft tumor growth by PC-3 cells; inset, excised tumors with respective mice (a-d). Experimental details were described in Materials and Methods.
Representative H&E-stained sections from PC-3 xenograft tumors and the characteristics of these tumors were analyzed (e-h). The expression of COX-2 (i-l ),
MMP-2 (m-p ), and neovascularization (vWF expression; q-t ) were visualized by immunofluorescence study using their specific antibodies. COX-2, MMP-2, and vWF
were stained with FITC-conjugated IgG (green ). B, levels of PGE2 production in these mice were determined from mice plasma by enzyme immunoassay. Three
mice were used in each set of experiments.
Table 1. Effect of COX-2 inhibition and EP2 receptor
blocking on osteopontin-induced prostate tumor growth in
nude mice
No. mice Treatments Tumor wt
(fold changes)
3 Control 1.00 F 0.13
3 Osteopontin 2.83 F 0.17
3 Osteopontin + celecoxib (1,500 ppm) 0.52 F 0.14
3 Osteopontin + EP2 antibody (20 Ag) 0.12 F 0.10
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In prostate cancer, PKCa plays a key role in the regulation
of downstream oncogenic molecules (34). Recent reports also
revealed that activation of PKCa is required for the survival and
growth of androgen-independent human prostate cancer cells
(41–43). However, it is not well established how osteopontin regu-
lates PKCa activation and PKCa-dependent downstream signaling
events in prostrate carcinoma. In this study, we provide evidences
that PKCa plays an important role in osteopontin-induced c-Src/
NIK–mediated IKKa/h-dependent NF-nB phosphorylation, which
ultimately controls COX-2 expression. Recently, we have shown the
involvement of the NIK/IKK/NF-nB signaling pathway in osteo-
pontin-induced expression of downstream effecter molecules that
regulate melanoma and breast tumor progression (21, 27). In this
study, we report that osteopontin regulates PKCa/c-Src–mediated
Table 2. Characteristics of the xenograft tumors from experimental mice
Tumor characteristics Control Osteopontin (0.5 Amol/L) Osteopontin (0.5 Amol/L) +
celecoxib (1,500 ppm)
Osteopontin (0.5 Amol/L) +
EP2 antibody (20 Ag)
Tumor infiltration Moderate Very high Moderate to poor Poor
Vessel formation Poor High Moderate to poor Negligible
Mitotic features/hpf 4-6 12-16 2-4 1-3
Tumor giant cells Less Plenty Scanty Very less
Nuclear polymorphism Moderate nuclear
size variation
Marked nuclear size variation Less nuclear size variation Small regular uniform
nucleus
Figure 7. Expressions of osteopontin (OPN ), COX-2, MMP-2, and NF-nB; p65 localization; and their correlation with human prostate cancer progression and
angiogenesis in different pathological grades. A, prostate tumor specimens were collected from a local hospital with informed consent. The gradations of these
specimens were done according to the Gleason grading system by H&E staining (a-c ). The levels of osteopontin (d-f ), COX-2 (j-l ), vWF (m-o ), and MMP-2 (p-r)
expression and cellular localization of p65 (g-i ) were detected by immunohistochemical studies using their specific antibodies. Osteopontin, vWF, and MMP-2
were stained with FITC (green ), whereas COX-2 and p65 (NF-nB) were stained with TRITC (red)–conjugated IgG, and the nucleus was counterstained with
4¶,6-diamidino-2-phenylindole (blue ). B, schematic representation of osteopontin-induced PKCa/c-Src/IKK/NF-nB–mediated COX-2 expression leading to enhanced
PGE2 production and MMP-2 activation that further induces tumorigenesis and angiogenesis via autocrine and paracrine mechanisms.
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IKK activation followed by NF-nB phosphorylation. Moreover, the
results showed that overexpression of super-repressor form of InBa
significantly suppressed osteopontin-induced COX-2 expression,
suggesting that NF-nB act as the key transcription factor in
regulation of COX-2 expression and further showed the dispens-
ability of the PKCa/c-Src/IKK/NF-nB signaling cascade in osteo-
pontin-induced COX-2 expression.
It is well established that increased level of PGE2 production and
MMP-2 activation is associated with enhanced expression of COX-2
in many cancers (44, 45). Administration of COX-2 inhibitors has
been reported to suppress PGE2 production and MMP-2 activation
in various cancers (46–48). Recent reports also indicated that PGE2
could also induce MMP-2 activation in cancer cells (49). Our data
showed that inhibition of upstream signaling pathway or treatment
with COX-2 inhibitor (celecoxib) significantly suppressed osteo-
pontin-induced PGE2 production and MMP-2 activation.
Recent findings indicated that COX-2-specific inhibitors signif-
icantly suppressed tumor growth in prostate cancer (50).
Interestingly, our studies showed that NSAID celecoxib and
NS398 (COX-2-selective inhibitor) significantly suppressed osteo-
pontin-induced PC-3 cells migration and invasion. The in vivo
xenograft tumor experiment indicated that mice fed with celecoxib
showed significant reduction in osteopontin-induced tumor
growth, and this study suggested that COX-2 could be an effective
target in caner therapy.
Tumor cell–derived PGE2 can contribute tumor progression
by regulating the cell motility/invasiveness and inducing angio-
genesis (8–10). Among PGE2 receptors, EP2 is expressed in both
prostate cancer and endothelial cells (39, 51). Moreover, the
development of selective antagonists against the EP2 receptor has
the potential to improve antitumor activity, and EP2 receptor
antagonist may be more specific than the use of COX-2 inhibitors
(52). Sung et al. showed that tumors from wt EP2 mice produced
more blood vessels than those of knockout mice (53). In our study,
we showed that the blocking the EP2 receptor by specific blocking
antibody suppressed osteopontin-induced prostate cancer (PC-3)
and endothelial cell motility and invasiveness. Furthermore, we
also find that administration of anti-EP2 blocking antibody
significantly suppressed osteopontin-induced mice xenograft
tumor progression.
Our study showed the detailed molecular mechanism by which
osteopontin induces cell migration, invasion, and tumor progres-
sion through induction of COX-2 expression and PGE2 production
(Fig. 7B). Our results further warrant that the mechanism shown in
the mouse model underlies the human pathology and a clear
understanding of osteopontin and COX-2 regulation could
illuminate cellular changes that accompany prostate cancer
progression and may facilitate the development of novel thera-
peutic approaches to suppress osteopontin-regulated PKCa/IKK/
NF-nB–mediated COX-2 expression and thereby controlling tumor
progression and angiogenesis.
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